New hope for advanced endometrial cancer: Triple-Drug combo enters safety testing

NCT ID NCT05106127

Not yet recruiting Disease control Sponsor: Evergreen Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding a repurposed drug called EG-007 to the standard combination of lenvatinib and pembrolizumab is safe for people with advanced or recurrent endometrial cancer. The study will enroll 28 adults whose cancer has progressed after platinum chemotherapy. Researchers will monitor side effects and tolerability, and participants who do well may continue treatment long-term.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EG-007 (a repurposed drug) plus lenvatinib and pembrolizumab
What this could lead to: If successful, this could provide a new treatment option for advanced endometrial cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is a small, early-phase safety study with only 28 participants. It is not yet recruiting, so results are uncertain. Adding a third drug may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED ENDOMETRIAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.